Grifols (GIKLY) Retained Earnings (2010 - 2025)
Grifols (GIKLY) reported Retained Earnings of $4.9 billion for Q4 2025, up 487.48% on a YoY basis from $829.2 million in Q4 2024, and up 487.48% quarter-over-quarter from $829.2 million in Q4 2024.
Grifols (GIKLY) Retained Earnings (2010 - 2025) Analysis & Trends
Grifols has reported Retained Earnings for 16 years, with the latest figure at $4.9 billion in Q4 2025.
- For the quarter ending Q4 2025, Retained Earnings rose 487.48% year-over-year to $4.9 billion; the trailing twelve-month figure through Dec 2025 stood at $4.9 billion (up 487.48% YoY), and the FY2025 full-year result was $4.9 billion, up 487.48% from the prior year.
- Retained Earnings for Q4 2025 stood at $4.9 billion, up from $829.2 million in the prior quarter.
- The five-year high for Retained Earnings was $4.9 billion in Q4 2025, with the low at $215.9 million in Q4 2021.
- Historically, Retained Earnings has averaged $2.9 billion across 5 years, with a median of $4.1 billion in 2022.
- Annual changes were most pronounced in 2021 — Retained Earnings sank 95.21% — and 2022, when it jumped 1815.37%.
- Grifols' Retained Earnings stood at $215.9 million in 2021, then jumped by 1815.37% to $4.1 billion in 2022, then gained by 5.14% to $4.3 billion in 2023, then plunged by 80.93% to $829.2 million in 2024, then soared by 487.48% to $4.9 billion in 2025.
- The last three Retained Earnings figures came in at $4.9 billion (Q4 2025), $829.2 million (Q4 2024), and $4.3 billion (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 1.90 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 29.51 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | -14.83 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -17.87 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 66.72 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | -190.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 78.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -7.20 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -1.37 Bn |
| 10 | Grifols | - | - | - | 4.87 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.87 Bn |
| Dec 31, 2024 | 829.23 Mn |
| Dec 31, 2023 | 4.35 Bn |
| Dec 31, 2022 | 4.14 Bn |
| Dec 31, 2021 | 215.90 Mn |
| Dec 31, 2020 | 4.50 Bn |
| Sep 30, 2020 | 4.71 Bn |
| Mar 31, 2020 | 4.44 Bn |
| Dec 31, 2019 | 3.33 Bn |
| Sep 30, 2019 | 3.10 Bn |
| Dec 31, 2018 | -28.12 Mn |
| Sep 30, 2018 | 2.85 Bn |
| Jun 30, 2018 | 2.93 Bn |
| Mar 31, 2018 | 3.73 Bn |
| Dec 31, 2017 | 2.39 Bn |
| Jun 30, 2017 | 2.23 Bn |
| Dec 31, 2016 | 1.83 Bn |
| Sep 30, 2016 | 1.89 Bn |
| Jun 30, 2016 | -5.12 Mn |
| Dec 31, 2015 | 1.50 Bn |